境界切除可能膵臓がん患者を対象としたTTI-101と放射線療法の併用の第1/2相試験
The survival rate for patients with pancreatic cancer remains at a dismal 10% or less at 5 years, and although trials integrating stereotactic body radiation therapy (SBRT) alone have shown improvement in local control, initial invigoration of immune response, and relief of symptom burden, SBRT has not demonstrated any improvement in survival. Preclinical research has established that STAT3 inhibition given concurrently with SBRT and in the maintenance phase acts as a synergistic agent that enhances the pro-inflammatory effects of SBRT while reducing its undesired effects (including fibrosis and immunosuppression). This study exploits the window of opportunity post-chemotherapy to advance the hypothesis that the addition of STAT3 inhibition in combination with SBRT will be safe and will enhance 2-year progression-free survival.
調査の概要
研究の種類
入学 (推定)
段階
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:Sana Karam, M.D., Ph.D.
- 電話番号:314-273-3240
- メール:sanadkaram@wustl.edu
研究場所
-
-
Colorado
-
Aurora、Colorado、アメリカ、80045
- 完了
- University of Colorado
-
-
Missouri
-
St Louis、Missouri、アメリカ、63110
- 募集
- Washington University School of Medicine
-
副調査官:
- Olivia Aranha, M.D., Ph.D.
-
副調査官:
- Kian-Huat Lim, M.D.
-
副調査官:
- Patrick Grierson, M.D., Ph.D.
-
副調査官:
- Dominic Sanford, M.D.
-
副調査官:
- Rama Suresh, M.D.
-
副調査官:
- Caron Rigden, M.D.
-
副調査官:
- Moh'd Khushman, M.D.
-
副調査官:
- Roheena Panni, M.D.
-
副調査官:
- Nikolaos Andreatos, M.D.
-
副調査官:
- Ramon Jin, M.D., Ph.D.
-
副調査官:
- Michael Waters, M.D., Ph.D.
-
副調査官:
- Chunjie Li, M.D., Ph.D.
-
コンタクト:
- Sana Karam, M.D., Ph.D.
- 電話番号:314-273-3240
- メール:sanadkaram@wustl.edu
-
主任研究者:
- Sana Karam, M.D., Ph.D.
-
副調査官:
- Joseph Harms, Ph.D., DABR
-
副調査官:
- Trang Nguyen, M.D.
-
副調査官:
- Ben Tan, M.D.
-
副調査官:
- Junxiao Hu, Ph.D.
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Pathologically confirmed pancreatic adenocarcinoma that is borderline resectable or locally advanced as defined by NCCN guidelines, with no expected arterial resection/reconstruction.
-
Patients who are borderline resectable must have completed standard of care induction chemotherapy between 1 and 3 weeks prior to planned start of TTI-101 + SBRT. Patients who exceed this window may be considered for enrollment if they complete an additional cycle of induction chemotherapy prior to initiation of study treatment (per provider discretion). The receipt and/or amount of induction chemotherapy cycles allowed will be left to the discretion of the treating medical oncologist. There is no timing restriction or chemotherapy receipt for patients with locally advanced disease.
-
At least 18 years of age.
-
ECOG performance status ≤ 2
-
Adequate bone marrow and organ function as defined below:
- Absolute neutrophil count ≥ 1.0 K/cumm
- Platelets ≥ 70 K/cumm
- Hemoglobin ≥ 9.0 g/dL (patients may be transfused to meet this criterion)
- Total bilirubin ≤ 2 mg/dL
- AST(SGOT)/ALT(SGPT) ≤ 3.0 x IULN
- Serum albumin ≥ 2.8 g/dL
- Ionized calcium ≤ 1.5 mmol/L, calcium ≤ 12 mg/dL, or corrected serum calcium ≤ IULN)
- Measured creatinine clearance > 40 mL/min or calculated creatinine clearance > 40 mL/min by Cockcroft-Gault or by 24-hour urine collection for determination of creatinine clearance (calculations in protocol).
-
Able to swallow pills and has been deemed an appropriate candidate for investigational TTI-101 treatment based on the opinion of both the treating radiation oncologist and the treating medical oncologist.
-
INR and aPTT ≤ 1.5 x IULN unless patient is receiving anticoagulant therapy (in which case INR and PTT must be within therapeutic range of intended use of anticoagulants)
-
The effects of TTI-101 on the developing human fetus are unknown. For this reason, women of childbearing potential and men must agree to use at least 1 highly effective method of contraception from screening through the duration of study participation, and for 30 days after last dose of TTI-101. Should a woman become pregnant or suspect she is pregnant while participating in this study or should a man suspect he has fathered a child, s/he must inform the treating physician immediately.
-
Agreement to adhere to Lifestyle Considerations throughout study duration.
-
Ability to understand and willingness to sign an IRB approved written informed consent document.
Exclusion Criteria:
- Prior irradiation of pancreatic cancer in the past 2 years.
- Prior or concurrent malignancy whose natural history has the potential to interfere with the safety or efficacy assessment of the investigational regimen. Patients with prior or concurrent malignancy that does NOT meet that definition are eligible for this trial.
- Currently receiving any other investigational agents or has participated in a study of an investigational agent or using an investigational device overlapping with study treatments within 3 months preceding study entry at the discretion of the PI.
- A history of allergic reactions attributed to compounds of similar chemical or biologic composition to TTI-101 or other agents used in the study.
- Uncontrolled intercurrent illness including but not limited to: ongoing or active infection (fungal, bacterial, or viral (including COVID-19)), sepsis, acute and chronic active infectious disorders (including viral and nonmalignant medical illnesses that are uncontrolled or whose control may be jeopardized by the complications of this study therapy), and chronic pancreatitis. Patients with a recent COVID-19 diagnosis must have fully recovered from all COVID-19 symptoms for 2 weeks prior to the start of study treatment.
- Significantly impaired cardiac function such as symptomatic congestive heart failure with NYHA Class III or IV, unstable angina pectoris, myocardial infarction within the last 12 months prior to study entry, serious cardiac arrhythmia (including QTc prolongation of > 470 ms and/or pacemaker), or prior diagnosis of congenital long QT syndrome.
- Ongoing toxicity due to induction chemotherapy, unless returned to baseline or grade 1 or less (except alopecia and labs noted in inclusion criterion #5).
- Has had major surgery within 3 weeks prior to starting TTI-101 or has not recovered from major side effects due to surgery.
- Presence of pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequent). Participants with indwelling catheters for control of effusions or ascites are allowed.
- History of cerebrovascular accident or stroke within the previous 2 years.
- History of hepatic encephalopathy.
- Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation).
- History of malabsorption or other chronic gastrointestinal disease or condition that may hamper compliance or absorption of TTI-101.
- Pregnant and/or breastfeeding. Women of childbearing potential must have a negative serum or urine pregnancy test within 5 days of study entry.
- HIV-infected if not on effective anti-retroviral therapy with undetectable viral load for 6 months. Patients with HIV who are receiving effective anti-retroviral therapy and have had an undetectable viral load for at least 6 months are eligible. HIV testing not required in the absence of known history of infection.
- Evidence of chronic hepatitis B virus (HBV) that is detectable on suppressive therapy. Patients with evidence of chronic HBV infection with undetectable HBV viral load on suppressive therapy are eligible. HBV testing not required in the absence of known history of infection.
- History of hepatitis C virus (HCV) infection that has not been cured or that has a detectable viral load. Patients with a history of HCV that has been treated and cured are eligible. Patients with HCV infection who are currently on treatment and have an undetectable HCV viral load are eligible. HCV testing not required in the absence of known history of infection.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:順次割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:TTI-101 + SBRT Dose Level 0 (original starting dose)
|
Given at the assigned dose assigned in the protocol. Given at the assigned dose and fractions assigned in the protocol.
他の名前:
|
|
実験的:TTI-101 + SBRT Dose Level -1 (WUSM starting dose)
|
Given at the assigned dose assigned in the protocol. Given at the assigned dose and fractions assigned in the protocol.
他の名前:
|
|
実験的:TTI-101 + SBRT Dose Level -2
|
Given at the assigned dose assigned in the protocol. Given at the assigned dose and fractions assigned in the protocol.
他の名前:
|
|
実験的:TTI-101 + SBRT Expansion Phase
|
Given at the assigned dose assigned in the protocol. Given at the assigned dose and fractions assigned in the protocol.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) of TTI-101 and SBRT
時間枠:Through completion of follow-up (estimated to be 2 years and 3 months)
|
|
Through completion of follow-up (estimated to be 2 years and 3 months)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Progression-free survival (PFS)
時間枠:2 years
|
PFS is defined as the time from treatment initiation to documented disease progression or death from any cause. The 2-year PFS probability will be reported as a descriptive summary measure. |
2 years
|
|
Overall survival (OS)
時間枠:2 years
|
OS is defined as the time from treatment initiation to death from any cause. The 2-year OS probability will be reported as a descriptive summary measure. |
2 years
|
|
Pathologic response rate
時間枠:At the time of surgery (estimated to be 5 weeks)
|
|
At the time of surgery (estimated to be 5 weeks)
|
|
R0 resection rate among patients who undergo surgical resection
時間枠:At the time of surgery (estimated to be 5 weeks)
|
R0 resection is defined as microscopic tumor clearance in the pancreatic resection specimen. |
At the time of surgery (estimated to be 5 weeks)
|
|
Frequency of adverse events
時間枠:From start of treatment through 90 days after last dose of TTI-101 (estimated to be 6 months)
|
Graded according to NCI CTCAE v 5.0. |
From start of treatment through 90 days after last dose of TTI-101 (estimated to be 6 months)
|
協力者と研究者
捜査官
- 主任研究者:Sana Karam, M.D., Ph.D.、Washington University School of Medicine
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。